Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.61 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | NCF1 | P14598 | 3/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30824514 | 0.80 | GRM5 (0.59) | GRM5KCNH2TTRCYP1A2NCF1 | |
| SCHEMBL6861227 | 0.77 | GRM5 (0.42) | GRM5CYP1A2ALDH1A1NPC1RAB9A | |
| SCHEMBL22074993 | 0.77 | GRM5 (0.47) | GRM5KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL12884286 | 0.76 | GRM5 (0.65) | GRM5KCNH2TTRCYP1A2NCF1 | |
| SCHEMBL18751060 | 0.76 | GRM5 (0.59) | GRM5KCNH2TTRCYP1A2NCF1 | |
| SCHEMBL6854919 | 0.76 | GRM5 (0.59) | GRM5KCNH2TTRCYP1A2NCF1 | |
| SCHEMBL15877252 | 0.76 | GRM5 (1.00) | GRM5KCNH2TTRCYP1A2ALDH1A1 | |
| SCHEMBL10788654 | 0.75 | GRM5 (0.53) | GRM5KCNH2TTRCYP1A2NCF1 | |
| SCHEMBL20915796 | 0.75 | TTR (0.57) | GRM5KCNH2TTRBACE1ALDH1A1 | |
| SCHEMBL5778843 | 0.74 | GRM5 (0.62) | GRM5KCNH2TTRCYP1A2NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946431-B2 | 2-(substituted ethynyl)quinoline derivatives as mGLUr5 antagonists | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-02-03 | — | — | US | disclosed |
| US-8927559-B2 | Quinazolinone-type compounds as CRTH2 antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927559-B2 | Quinazolinone-type compounds as CRTH2 antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140206876-A1 | 2-(Substituted ethynyl)quinoline Derivatives as mGLUr5 Antagonists | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-07-24 | — | — | US | disclosed |
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| WO-2012051036-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-7342026-B2 | Substituted quinolines for the treatment of protozoa and retrovirus co-infections | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (FR) | 2008-03-11 | — | — | US | disclosed |
| EP-1351940-B1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | INST RECH DEVELOPPEMENT IRD (FR) | 2007-07-25 | — | — | EP | disclosed |
| US-20050165052-A1 | Substituted quinolines for the treatment of protozoa and retrovirus co-infections | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (FR) | 2005-07-28 | — | — | US | disclosed |
| EP-0937045-B1 | N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY | ALLERGAN INC (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-1351940-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | Institut de Recherche pour le Développement ( IRD) (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002057238-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD) (FR) | 2002-07-25 | — | — | WO | disclosed |
| EP-0937045-A1 | N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY | Allergan Sales, Inc. (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0876345-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-11 | — | — | EP | disclosed |
| WO-1998019999-A1 | N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY | ALLERGAN SALES, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| US-5739338-A | SKIN DISORDERS, ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENTS, VISION DEFECTS, VIRICIDES, IMMUNOSUPPRESSANTS | ALLERGAN (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1997014681-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, NR3C2, HRH1 | GRM5 403/4885KCNH2 262/4885TTR 3964/4885 |
| US-20050165052-A1 | Substituted quinolines for the treatment of protozoa and retrovirus co-infections | C1S, C5, NSFL1C | GRM5 2484/4885KCNH2 259/4885TTR 2427/4885 |
| US-20140206876-A1 | 2-(Substituted ethynyl)quinoline Derivatives as mGLUr5 Antagonists | GRM5, GRIK5, GRIA4 | GRM5 1/4885KCNH2 1318/4885TTR 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.